Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure
Public ClinicalTrials.gov record NCT04286438. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
Study identification
- NCT ID
- NCT04286438
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- SFJ Pharmaceuticals, Inc.
- Industry
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Interventions
- Bentracimab (PB2452) Infusion Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2020
- Primary completion
- Sep 8, 2024
- Completion
- Sep 8, 2024
- Last update posted
- Oct 20, 2024
2020 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Florida Health, Jacksonville | Jacksonville | Florida | 32209 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| Sinai Hospital of Baltimore | Baltimore | Maryland | 21215 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| North Kansas City Hospital | North Kansas City | Missouri | 64116 | — |
| Cox Medical Centers | Springfield | Missouri | 65807 | — |
| Sanford Medical Center Fargo | Fargo | North Dakota | 58104 | — |
| Ascension St. John Clinical Research Institute | Tulsa | Oklahoma | 74104 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04286438, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2024 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04286438 live on ClinicalTrials.gov.